In vivo coronary plaque histology in patients with stable and acute coronary syndromes. Relationships with hyperlipidemic status and statin treatment

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 189-195

  Pucci, Angela ^a   Sheiban, Imad ^b   Formato, Luisa ^b,e   Celeste, Angela ^a   Brscic, Elvis ^c   Moretti, Claudio ^b   De Bernardi, Alberto ^e   Alberti, Alessandro ^c   Bergamasco, Laura ^d   Trevi, Gianpaolo ^b   Fuster, Valentin ^f  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b University Division of Cardiology   (Italy)

^c Villa Maria Pia Hospital   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Coronary disease; Immunohistochemistry; Inflammation; Lipoproteins

Indexed keywords

ATORVASTATIN; GLYCOPHORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTIONAL ATHERECTOMY; ENDOTHELIUM CELL; FEMALE; HEART INFARCTION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHERECTOMY, CORONARY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; GLYCOPHORIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES;

EID: 34648846045     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.026     Document Type: Article

References (30)

1. Corti R., Hutter R., Badimon J.J., and Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombol 17 (2004) 35-44
2. Donald D., and Heistad M.D. Unstable coronary artery plaques. N Engl J Med 349 (2003) 2285-2287
3. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
4. Corti L., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions. Two years' follow-up by high-resolution non-invasive magnetic resonance. Circulation 106 (2002) 2884-2887
5. Libby P., and Masanori M. Mechanisms of plaque stabilization with statins. Am J Cardiol 91 (2003) S4b-S8b
6. Gomberg-Maitland M., Fuster V., Fayad Z.A., Badimon J.J., and Corti R. Statins and plaque stability. J Cardiovasc Risk 10 (2003) 161-167
7. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47 (2000) 648-657
8. Mason P.R., Walter M.F., and Jacob R.T. Effect of HMG-CoA reductase inhibitors on endothelial function. Circulation 109 (2004) 34-41 SII
9. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation 103 (2001) 926-933
10. Moulton K.S., Vakili K., Zurakowski D., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. PNAS 100 (2003) 4736-4741
11. Moreno P.R., Purushothaman R., Fuster V., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesion of human aorta. Implication for plaque vulnerability. Circulation 110 (2004) 2032-2038
12. Ignatescu M.C., Gharehbaghi-Schnell E., Hassan A., et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: in vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol 19 (1999) 2340-2347
13. Falk E., and Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 75 (1995) 3B-11B
14. Khurana R., Zhuang Z., Bhardwaj S., et al. Angiogenesis-dependent and -independent phases of intimal hyperplasia. Circulation 110 (2004) 2436-2443
15. Schaar J.A., Muller J.E., Falk E., et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, Santorini, Greece. Eur Heart J 25 (2004) 1077-1082
16. Maseri A., and Fuster V. Is there a vulnerabile plaque?. Circulation 107 (2003) 2068-2071
17. Moreno P.R., and Fuster V. The year in atherothrombosis. JACC 44 (2004) 2099-2110
18. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349 (2003) 2316-2325
19. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
20. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
21. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals. Lancet 360 (2002) 7-22
22. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
23. Kinlay S., and Selwyn A.P. Effect of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 91 (2003) S9b-S13b
24. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
25. Kinlay S., Timms T., Clark M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89 (2002) 1205-1207
26. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
27. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94 (1996) 3090-3097
28. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., and Fallon J.T. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 90 (1994) 775-778
29. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary artery disease. N Engl J Med 345 (2001) 1583-1592
30. Flugelman M.Y., Virmani R., Correa R., et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina: a clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 88 (1993) 2493-2500